GB Sciences, LSU Partner on Cannabinoid Research and Development Project for MS, Other Diseases

As debate continues about the effects of medical marijuana on multiple sclerosis (MS) and other diseases, cannabis company GB Sciences and Louisiana State University (LSU) have agreed on a cannabinoid research and development project.

This collaboration between a public and a private enterprise is a first in the therapeutic cannabis industry, according to a press release from GB Sciences. Louisiana permits the cultivation, extraction, processing, production, and sale of medicinal cannabis.

Specifically, the five-year Master Research and Development Agreement for the production of therapeutic cannabis targeting severe medical conditions and diseases is with LSU’s Agricultural Center. It results from a mutual wish to participate in joint projects related to the production of medicinal cannabis in the state.

Following a public bidding process, the center chose GB Sciences subsidiary GB Sciences Louisiana to cultivate and produce therapeutic cannabis for Louisiana patients with specific disorders, namely MS, cancer, human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS), cachexia (a condition that causes extreme weight loss and muscle wasting), seizure disorders, epilepsy, spasticity, Crohn’s disease (an inflammatory bowel disease), muscular dystrophy, glaucoma, Parkinson’s disease, muscle spasms, intractable pain, post-traumatic stress disorder, and some forms of autism.